Aclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052

Aclaris Therapeutics (ACRS) announced that it has initiated a placebo-controlled Phase 1b proof-of-concept trial in atopic dermatitis for ATI-052, the company’s potential best-in-class investigational bispecific anti-TSLP/IL-4Ralpha antibody. “We are experiencing strong momentum in the ATI-052 clinical development program including the recent positive Phase 1a interim results which demonstrated a strong safety and tolerability profile, extended pharmacokinetics, and concentration-dependent pharmacodynamics even at the lowest dose,” said Dr. Jesse Hall, Chief Medical Officer of Aclaris. “Further to this, we are excited to announce the initiation of the first POC Phase 1b trial in people living with atopic dermatitis. We expect to initiate the second Phase 1b POC trial in asthma this quarter as well. We intend to provide top line results from both trials in the second half of the year.”